Provided by Tiger Trade Technology Pte. Ltd.

Haemonetics

59.52
-0.5300-0.88%
Post-market: 59.520.00000.00%16:10 EDT
Volume:799.38K
Turnover:47.60M
Market Cap:2.77B
PE:16.30
High:60.04
Open:59.53
Low:59.04
Close:60.05
52wk High:87.32
52wk Low:47.32
Shares:46.47M
Float Shares:46.47M
Volume Ratio:0.94
T/O Rate:1.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.65
EPS(LYR):3.31
ROE:19.30%
ROA:6.45%
PB:3.03
PE(LYR):17.98

Loading ...

Haemonetics Receives FDA Clearance for Nexsys® Pcs Plasma Collection System With Persona® Plus Technology

THOMSON REUTERS
·
Feb 24

Haemonetics CEO Chris Simon Joins Raymond James Institutional Investors Conference Fireside Chat

Reuters
·
Feb 21

Haemonetics (HAE) Gets a Buy from BTIG

TIPRANKS
·
Feb 21

Haemonetics (HAE) Balances Softer Interventional Sales With Buybacks – What Story Does Guidance Tell?

Simply Wall St.
·
Feb 13

Haemonetics Corporation Releases 2024-2025 Corporate Responsibility Report

Reuters
·
Feb 13

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting

GlobeNewswire
·
Feb 11

Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting

GlobeNewswire
·
Feb 10

Haemonetics Earnings Call: Strong Core, IVT Drag

TIPRANKS
·
Feb 08

These Analysts Revise Their Forecasts On Haemonetics After Q3 Earnings

Benzinga
·
Feb 07

Stock Track | Haemonetics Plummets 5.04% Intraday Following Series of Analyst Price Target Cuts

Stock Track
·
Feb 06

Haemonetics price target lowered to $81 from $99 at Baird

TIPRANKS
·
Feb 06

Haemonetics Is Maintained at Outperform by Barrington Research

Dow Jones
·
Feb 06

Haemonetics price target lowered to $75 from $88 at Citi

TIPRANKS
·
Feb 06

Haemonetics Price Target Maintained With a $88.00/Share by BTIG

Dow Jones
·
Feb 06

Orchestra Biomed Unveils Vision for Growth With Updates on Pivotal Cardiovascular Trials and Strategic Partnerships

Reuters
·
Feb 06

Earnings Flash (HAE) Haemonetics Posts Fiscal Q3 Adjusted EPS $1.31, vs. FactSet Est of $1.22

MT Newswires Live
·
Feb 05

Haemonetics Outlook FY Organic Growth 0-2%

THOMSON REUTERS
·
Feb 05

Haemonetics Q3 Adjusted EPS USD 1.31 VS. Ibes Estimate USD 1.25

THOMSON REUTERS
·
Feb 05

GUIDANCE:(HAE) Haemonetics Expects Fiscal 2026 Adjusted EPS Range $4.90 - $5, vs. FactSet Est of $4.70

MT Newswires Live
·
Feb 05

Haemonetics Q3 Adj. EPS $1.31 Beats $1.25 Estimate, Sales $338.967M Beat $331.616M Estimate

Benzinga
·
Feb 05